Law360 (April 30, 2019, 4:52 PM EDT) -- If the promise of adaptive artificial intelligence (sometimes called machine learning) is to be achieved in the medical area, the U.S. Food and Drug Administration's regulation of medical devices is going to have to graduate from geometry to calculus. By its nature, machine learning changes the details of its output constantly.
The rigid regulatory model requiring FDA preapproval of all “major changes” (defined as anything that could affect product safety or effectiveness) that has served the FDA, and the public health, well for many years cannot handle adaptive artificial intelligence. The fundamental insight of the calculus was that it allowed measurement...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!